Moving from bench to bedside

Posted 30 September 2024 AM

Queensland policymakers came together with industry, academia and patient advocates from the Prostate Cancer Foundation of Australia last week at a roundtable co-hosted by Novartis and Queensland Health to launch a report and discuss the impact of emerging radiotherapies.

The Bench to Bedside: The promise of radioligand therapy report was written by health consultants Evohealth, and outlines three recommendations to promote the use of radiopharmaceuticals to treat cancer in Australia. To date, Australians have only had access to these treatments through clinical trials.

To see the whole article, please login